Cadila Healthcare has gained to a new high on the commencement of the next phase of H1N1 drug by Zydus Cadila.
The stock opened at Rs 805 and gained 2% to a new high of Rs 813. It is now trading with a 1.4% gain at Rs 810. Around 1,214 stocks have been traded on the BSE so far.
Pharma major Zydus Cadila has started the phase II and III of the clinical trials of its H1N1 vaccine as the first company in the country, while its competitors are close on its heels to come up with respective vaccines.
The demand for the H1N1 vaccine is expected to be around 60-80 million doses in India, and that the company would focus on marketing the product in India initially.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app